BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 22502770)

  • 1. Patient-reported quality of life during radiation treatment for localized prostate cancer: results from a prospective phase II trial.
    Chen RC; Zhang Y; Chen MH; McMahon E; Loffredo M; McPherson CP; Nguyen AU; Nguyen PL; D'Amico AV
    BJU Int; 2012 Dec; 110(11):1690-5. PubMed ID: 22502770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature.
    Budäus L; Bolla M; Bossi A; Cozzarini C; Crook J; Widmark A; Wiegel T
    Eur Urol; 2012 Jan; 61(1):112-27. PubMed ID: 22001105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
    Forsythe K; Blacksburg S; Stone N; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported quality of life during definitive and postprostatectomy image-guided radiation therapy for prostate cancer.
    Diao K; Lobos EA; Yirmibesoglu E; Basak R; Hendrix LH; Barbosa B; Miller SM; Pearlstein KA; Goldin GH; Wang AZ; Chen RC
    Pract Radiat Oncol; 2017; 7(2):e117-e124. PubMed ID: 28274402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
    Morton GC; Loblaw DA; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Keller B; Danjoux C; Szumacher E; Thomas G
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):811-7. PubMed ID: 19836166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy.
    Stone NN; Stock RG
    Brachytherapy; 2003; 2(1):32-9. PubMed ID: 15062161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
    Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
    Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient self-assessment of complications and quality of life after conformal neutron and photon irradiation for localized prostate cancer.
    Reddy SM; Ruby J; Wallace M; Forman JD
    Radiat Oncol Investig; 1997; 5(5):252-6. PubMed ID: 9372548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RTOG's first quality of life study--RTOG 90-20: a phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer.
    Watkins-Bruner D; Scott C; Lawton C; DelRowe J; Rotman M; Buswell L; Beard C; Cella D
    Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):901-6. PubMed ID: 7591900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer.
    Coen JJ; Paly JJ; Niemierko A; Weyman E; Rodrigues A; Shipley WU; Zietman AL; Talcott JA
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e201-9. PubMed ID: 21621343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life after whole pelvic versus prostate-only external beam radiotherapy for prostate cancer: a matched-pair comparison.
    Pinkawa M; Piroth MD; Holy R; Fischedick K; Klotz J; Székely-Orbán D; Eble MJ
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):23-8. PubMed ID: 20832182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported lower urinary tract symptoms, urinary incontinence, and quality of life after external beam radiotherapy for localized prostate cancer--15 years' follow-up. A comparison with age-matched controls.
    Fransson P
    Acta Oncol; 2008; 47(5):852-61. PubMed ID: 17899451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function.
    Chen RC; Clark JA; Talcott JA
    J Clin Oncol; 2009 Aug; 27(24):3916-22. PubMed ID: 19620493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of toxicity following high-dose-rate brachytherapy boost for prostate cancer: mature prospective phase I/II study results.
    Duchesne GM; Williams SG; Das R; Tai KH
    Radiother Oncol; 2007 Aug; 84(2):128-34. PubMed ID: 17561293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
    Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer active surveillance and health-related quality of life: results of the Finnish arm of the prospective trial.
    Vasarainen H; Lokman U; Ruutu M; Taari K; Rannikko A
    BJU Int; 2012 Jun; 109(11):1614-9. PubMed ID: 22044485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy.
    Moinpour CM; Hayden KA; Unger JM; Thompson IM; Redman MW; Canby-Hagino ED; Higgins BA; Sullivan JW; Lemmon D; Breslin S; Crawford ED; Southwest Oncology Group
    J Clin Oncol; 2008 Jan; 26(1):112-20. PubMed ID: 18165645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial.
    Yeoh EE; Fraser RJ; McGowan RE; Botten RJ; Di Matteo AC; Roos DE; Penniment MG; Borg MF
    Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):943-55. PubMed ID: 12605972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.